Ortho gets CE mark for slides that run 2 IVD tests off a single blood sample

Ortho says its dual-test slides can increase productivity while maintaining the same lab footprint. (Ortho)

Ortho Clinical Diagnostics has received a CE mark for its new multitest platform that allows laboratories to run two in vitro diagnostic tests simultaneously on one slide.

The company’s Vitros XT MicroSlide employs digital optics to increase productivity while requiring less blood be taken from patients, which Ortho described as important for vulnerable patients and those with venous access issues.

The individual, dual-test slides include paired assays for blood urea nitrogen and creatinine ratios; triglycerides and cholesterol; and glucose and calcium levels, all for use on the Vitros XT 7600 Integrated System. The platform is currently under review by the FDA.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

In a statement, Ortho said the system can improve turnaround time, and simplify inventory management and storage space.

RELATED: FDA approves Ortho’s next-generation Vitros HIV combo test

Late last year, the FDA approved Ortho’s HIV combination diagnostic—which detects both HIV-1 and HIV-2 antibodies, as well as the p24 antigen—for use on the Vitros 5600 system. The company described the combination test as being able to detect HIV-1 infections earlier than previous generations of the diagnostic.

Suggested Articles

The Chan Zuckerberg Initiative is awarding $17 million for advances in digital microscopy to allow researchers to view the subtleties of disease.

The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.

The level of interest in gene therapies has been laid bare by a report on Biogen’s pursuit of Nightstar Therapeutics.